Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer
- PMID: 20884032
- DOI: 10.1016/j.juro.2010.06.115
Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer
Abstract
Purpose: We elucidated the regulatory mechanism of adrenal androgen synthesis and examined the influence of pituitary-adrenal axis activity on prostate specific antigen during androgen deprivation therapy.
Materials and methods: A total of 72 patients with localized prostate cancer were prospectively studied based on blood samples before and after androgen deprivation therapy for 6 months. Serum pituitary hormones, androgens and prostate specific antigen were measured using highly sensitive assays.
Results: After androgen deprivation therapy serum levels of luteinizing hormone, follicle-stimulating hormone, testosterone, dehydroepiandrosterone sulfate, androstenedione and prostate specific antigen decreased compared with those at the baseline (all values p <0.001). No difference was noted between serum levels before and after androgen deprivation therapy in growth hormone (p = 0.098) and adrenocorticotropic hormone (p = 0.101). Each serum level of luteinizing hormone, follicle-stimulating hormone and growth hormone after androgen deprivation therapy was not correlated with the serum levels of androgens or prostate specific antigen. The serum adrenocorticotropic hormone level after androgen deprivation therapy was correlated with the serum levels of testosterone (p = 0.002), dehydroepiandrosterone sulfate (p = 0.002), androstenedione (p = 0.006) and prostate specific antigen (p <0.001). Serum dehydroepiandrosterone sulfate and androstenedione levels were also correlated with serum prostate specific antigen (p <0.001 and p = 0.002, respectively).
Conclusions: In patients treated with androgen deprivation therapy the pituitary-adrenal axis mediated by adrenocorticotropic hormone has a central role in the regulation of androgen synthesis. Serum adrenocorticotropic hormone and adrenal androgen concentrations were correlated with the posttreatment prostate specific antigen. Adrenocorticotropic hormone mediated androgen synthesis is a potential target for advanced androgen deprivation therapy.
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial comment.J Urol. 2010 Nov;184(5):1976. doi: 10.1016/j.juro.2010.06.161. J Urol. 2010. PMID: 20884031 No abstract available.
Similar articles
-
Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.Prostate. 2010 Sep 15;70(13):1395-401. doi: 10.1002/pros.21174. Prostate. 2010. PMID: 20687212
-
Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.Urol Oncol. 2012 Sep;30(5):596-601. doi: 10.1016/j.urolonc.2010.11.001. Epub 2011 Apr 1. Urol Oncol. 2012. PMID: 21458314
-
Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.Prostate. 2010 Feb 1;70(2):155-61. doi: 10.1002/pros.21047. Prostate. 2010. PMID: 19760629 Clinical Trial.
-
Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.Prostate. 2011 Apr;71(5):550-7. doi: 10.1002/pros.21266. Epub 2010 Oct 13. Prostate. 2011. PMID: 20945429 Review.
-
Advantages of total androgen blockade in the treatment of advanced prostate cancer.Semin Oncol. 1988 Apr;15(2 Suppl 1):53-61. Semin Oncol. 1988. PMID: 3285484 Review.
Cited by
-
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.Prostate Cancer Prostatic Dis. 2016 Jun;19(2):191-6. doi: 10.1038/pcan.2016.2. Epub 2016 Feb 9. Prostate Cancer Prostatic Dis. 2016. PMID: 26857022
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical